Combined Cisplatinum and Laser Thermal Therapy for Palliation of Recurrent Head and Neck Tumors
نویسندگان
چکیده
منابع مشابه
Combined Cisplatinum and Laser Thermal Therapy for Palliation of Recurrent Head and Neck Tumors
In recent years endoscopically controlled laser-induced thermal therapy (LITT) has been increasingly accepted as a minimally invasive method for palliation of advanced or recurrent head and neck or gastrointestinal cancer. Previous studies have shown that adjuvant chemotherapy can potentiate endoscopic laser thermal ablation of obstructing tumors leading to improved palliation in advanced cance...
متن کاملHead and Neck Tumors: Management of Primary Undifferentiated Pleomorphic Sarcoma
Introduction: Sarcomas account for 1% of all tumors originated in the head and neck regions in adults. They constitute a heterogeneous group of tumors of mesenchymal origin with multiple histological variants. The undifferentiated pleomorphic sarcoma (UPS) subtype is the most frequent variant with an incidence range of 2.7-38%. Materials and Methods: This retrospective...
متن کاملQuantification of Partial Volume Effects in Salivary Glands SPECT Images after Radiation Therapy of Head and Neck Tumors
Introduction: Radical radiation therapy of head and neck cancers may injure the salivary glands and reduce their function. Single-photon emission computed tomography (SPECT) images maybe used to evaluate function post-therapy. However, accurate quantification is hindered by the partial volume effects (PVEs). The present study involved the introduction of a PVEs quantif...
متن کاملStudy of Thermal Effects of Laser on the Treatment of Head and Neck Cancer with Multi-Layered Nanoparticles
This article has no abstract.
متن کاملSupportive therapy in medical therapy of head and neck tumors
Fever during neutropenia may be a symptom of severe life threatening infection, which must be treated immediately with antibiotics. If signs of infection persist, therapy must be modified. Diagnostic measures should not delay treatment. If the risk of febrile neutropenia after chemotherapy is ≥ 20%, then prophylactic therapy with G-CSF is standard of care. After protocols with a risk of febrile...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diagnostic and Therapeutic Endoscopy
سال: 2000
ISSN: 1070-3608
DOI: 10.1155/dte.6.133